SLC47A2
MOLECULAR TARGETsolute carrier family 47 member 2
SLC47A2 (solute carrier family 47 member 2) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting SLC47A2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | imatinib | 5.47 | 236 |
| 2 | prazosin | 5.15 | 172 |
| 3 | indinavir | 4.84 | 125 |
| 4 | zafirlukast | 3.89 | 48 |
| 5 | pantoprazole | 3.37 | 28 |
| 6 | dabigatran | 3.09 | 21 |
| 7 | camostat | 3.04 | 20 |
| 8 | bithionol | 2.89 | 17 |
| 9 | epinastine | 2.40 | 10 |
| 10 | Ondansetron | 1.39 | 3 |
| 11 | Chlorhexidine | 0.69 | 1 |
| 12 | Irinotecan | 0.69 | 1 |
| 13 | pentamidine | 0.69 | 1 |
| 14 | Ritonavir | 0.69 | 1 |
| 15 | Topotecan | 0.69 | 1 |
About SLC47A2 as a Drug Target
SLC47A2 (solute carrier family 47 member 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented SLC47A2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
SLC47A2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.